BioAtla, Inc. secures $7.5 million in pre-paid advance agreements with Yorkville Advisors Global and Anson Advisors Inc. to support operations during finalization of a strategic partnership. The company remains on track to complete the transaction by year end. Tungsten Advisors acted as the sole placement agent for the agreements, ensuring BioAtla’s operational momentum. The agreements include key terms such as $7.5 million purchased at 95% of face value and interest accruing at 4%. BioAtla’s CAB antibody therapeutics target solid tumors with more selective targeting and greater efficacy. Ozuriftamab vedotin (Oz-V) and CAB-EpCAM x CAB-CD3 Bispecific T-cell Engager Antibody are among the company’s innovative products in development.

Read more at GlobeNewswire: BioAtla Enters into Agreements for up to $22.5 Million